A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT01106651. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control on their current diabetes treatment regimen.
Study identification
- NCT ID
- NCT01106651
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 716 participants
Conditions and interventions
Conditions
Interventions
- Canagliflozin 100 mg Drug
- Canagliflozin 300 mg Drug
- Antihyperglycemic agent(s) Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 55 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2010 (Type not available)
- Primary completion
- Nov 2011 (Actual)
- Completion
- May 2013 (Actual)
- Last update posted
- Nov 4, 2014
2010 – 2013
United States locations
- U.S. sites
- 34
- U.S. states
- 16
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Glendale | Arizona | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Carmichael | California | — | — |
| Not listed | Citrus Heights | California | — | — |
| Not listed | Fair Oaks | California | — | — |
| Not listed | Roseville | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Walnut Creek | California | — | — |
| Not listed | Daytona Beach | Florida | — | — |
| Not listed | Fleming Island | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Waltham | Massachusetts | — | — |
| Not listed | Pahrump | Nevada | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Cary | North Carolina | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Wilmington | North Carolina | — | — |
| Not listed | Bismarck | North Dakota | — | — |
| Not listed | Franklin | Ohio | — | — |
| Not listed | Mt. Pleasant | South Carolina | — | — |
| Not listed | Bristol | Tennessee | — | — |
| Not listed | Carrollton | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Irving | Texas | — | — |
| Not listed | Plano | Texas | — | — |
| Not listed | Richardson | Texas | — | — |
| Not listed | Renton | Washington | — | — |
| Not listed | Tacoma | Washington | — | — |
| Not listed | Wenatchee | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01106651, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2014 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01106651 live on ClinicalTrials.gov.